DEC 06, 2018 3:15 PM PST

Targeting CB1 Receptors With Antibodies

WRITTEN BY: Amy Loriaux

A recent press release from the pharmaceutical company Integral Molecular, written by Kate Kadash-Edmondson, has demonstrated the safety of a new therapeutic target for the endocannabinoid system (ECS): monoclonal antibodies for the ECS receptor CB1. Previous attempts at targeting this receptor have been tried before for various other ailments, such as obesity, as reviewed in earlier editions of this newsletter, only to have their products fail due to unforeseen adverse psychiatric side effects. In the case, a typical molecular compound (i.e. old fashion pill) was used to target CB1. Integral Molecular is going about it a new way, via the use of monoclonal antibodies (mAb). See video below for a crash course on mAb therapy.

Photo Source: UnSplash.com

A brief summary of the ECS. The ECS is made up of neurotransmitters ([NTs] anandamide, 2-AG, and various other compounds), receptors (most famous are the CB1 and CB2 receptors) and the various enzymes that are used to produce and degrade ECS NTs. The ECS runs all throughout our body and is responsible for several regulating mechanisms, including homeostasis, pain modulation, appetite, memory, and perception. Targeting the receptors in the ECS can have both effects in the periphery (e.g. modulating pain) and the central nervous system (CNS) (e.g. euphoria). The trick in using the ECS to treat a physical disease in the peripheral nervous system (PNS) is keeping it from crossing the blood-brain barrier, a challenge many therapies face.

Integral Molecular is trying a new approach, one made famous by the push in immuno-oncology therapies. Because it is a mAb, it is too large to cross the blood brain barrier. So it sticks around in the PNS, which makes it a great alternative if you are concerned about neurological or psychiatric side effects. Integral Molecular is targetting the CB1 receptor in the PNS to treat the liver disease nonalcoholic steatohepatitis (NASH) and metabolic disorders. It turns out that the CB1 receptor may be involved in inflammation and ultimately liver injury. With the mAb approach, scientists can antagonize (i.e. block) the CB1 receptors in the liver to prevent further damage.

Photo Source: pixabay.com

Integral Molecular has just received a grant to study their drug in preclinical models. We are not sure what the future holds for this treatment, but hopefully, with its ability to stay within the PNS, its specificity that comes with mAbs, and the sound scientific reasoning to indicate that CB1s do contribute to liver problems, this sort of treatment can be used for many more ECS-related diseases. The video below is a quick guide on the therapeutic applications of mAbs in treating all sorts of diseases. This type of immunotherapy may one day replace the pharmacological model of treatment, leading to fewer side effects and more efficacy.

Video Source: YouTube.com

Sources: IntegralMolecular.com, LinkedIn.com, Labroots.com, Wikipedia.com - Monoclonal Antibodies, Cold Spring Harbor Perspectives in Biology, Journal of Hepatology

Correction: In an earlier publication of this article it was stated that Integral Molecular were in Phase II clinical trials. They are not, instead they are still in the preclinical phase.

About the Author
  • I currently work at a small CRO involved in clinical trial management.
You May Also Like
JUL 08, 2021
Health & Medicine
Cannabinoid Hyperemesis Syndrome Is Helped by Hot Pepper Cream
JUL 08, 2021
Cannabinoid Hyperemesis Syndrome Is Helped by Hot Pepper Cream
A new research review suggests that capsaicin cream, rubbed into the abdomen, may help with the symptoms of cannabinoid ...
JUL 31, 2021
Cannabis Sciences
Can CBD Treat Psoriasis?
JUL 31, 2021
Can CBD Treat Psoriasis?
With cannabidiol (CBD) becoming increasingly available, many are wondering about its utility in treating various conditi ...
SEP 16, 2021
Cannabis Sciences
Cannabis Use and Exercise- A Dire Need for High-quality Evidence
SEP 16, 2021
Cannabis Use and Exercise- A Dire Need for High-quality Evidence
It should come as no surprise that exercise is good for our health. Regular exercise reduces the risks of serious chroni ...
OCT 01, 2021
Cannabis Sciences
Smartphone Technology Could Help Predict Cannabis Intoxication
OCT 01, 2021
Smartphone Technology Could Help Predict Cannabis Intoxication
Cannabis use can affect the body in a range of ways, including slowing response time. A slower response time affects our ...
OCT 14, 2021
Cannabis Sciences
Cannabis Use for Migraine Relief-New Horizons
OCT 14, 2021
Cannabis Use for Migraine Relief-New Horizons
Imagine having to leave a meeting or special occasion to go into a room, close the blinds, lie on the floor, and wait fo ...
OCT 29, 2021
Cannabis Sciences
Hempcrete's Role in Energy Efficient Building Materials
OCT 29, 2021
Hempcrete's Role in Energy Efficient Building Materials
As more people explore the potential of hemp building materials, research studies are focusing on hempcrete performance ...
Loading Comments...